诺诚健华：港股公告：截至2023年12月31日止年度全年业绩公告
InnoCare Pharma
20231231
2023123120221231
20232022
738,537625,404(128,435)(143,397)610,102482,007244,153198,199(366,891)(438,611)(751,176)(639,139)(193,520)(181,556)(92,674)(291,167)(645,632)(893,727)
(490,668)(473,691)
20231231
20221231
8,224,5968,697,92720221231625.418.1%20231231738.5
20221231565.9
18.5%20231231670.720221231482.026.6%20231231610.120231231
82.6%2022123177.1%5.5%
20221231198.220231231244.2
20221231136.955.420231231192.3
202212311,550.520231231
1,404.3(i)
20221231
438.671.720231231
366.9(ii)20232022
200.7(iii)112.020231231751.2
20221231893.727.8%20231231645.6
82.2
20232022
(645,632)(893,727)89,861290,55965,103129,477(490,668)(473,691)
R&D
TafasitamabICP-248ICP-B02ICP-490ICP-B05
NHLMM
20234
MZLBTK
NRDLCLL/SLLMCL20231231
?BTK670.72022565.918.5%
CSCO
MZLNDA20234
NMPAMZLBTKIRCORR
58.9%12PFSOS82.8%91%MZL
CLL/SLL2023III
2024NDA MCLII
20232024
FDAFDANDAIII MCLIII
MCDDLBCLIII
R-CHOPR-CHOPMCDDLBCL
ICP-B04TafasitamabCD19(Minjuvi
?
) B
DLBCLII2024
CDENDA2025NDA2022Tafasitamab
BLAASCTDLBCL
Tafasitamab
DLBCLTafasitamabDLBCL
ASCTDLBCLtafasitamabCSCOASCTDLBCL
ICP-248
ICP-248B2BCL-2
ICLL/SLLMCLNHL
BCL-2PK176100mg QD3CR2uMRDORR100%ICP-248CLL/SLLNHLICP-248
CLL/SLLIND20243IND20241ICP-B02 (CM355) ICP-B02CD20xCD3I/II
ICP-B02NHLPK
IVSCIVSCICP-B02FLDLBCL13ICP-B02≥6
ORR100%SC9ORR100%(9/9)(CRR)77.8%(7/9)2DLBCLCRICP-B02
ICP-B02NHL
IND
ICP-490 ICP-490
MMIICP-490
PDAiolos(IKZF3)Ikaro(IKZF1)20239INDCDEICP-490dexamethasoneICP-490MM
ICP-B05 (CM369)
ICP-B05C-C8CCR8
(2162.HK)IICP-B05NHL
ICP-B05150NHLICP-B05
3AE
TNHLPR
ICP-B05
BT
3.7%
20291,850
2023103iHealthcareAnalyst, Inc.BT
ITP
PoCIII202310
202420252023612ITPIIPoCEHA202350QD40%50QD(GC)(IVIG)75%6/8
BTKITPBTK SLEIIa
SRI-4
IIb2024
CDE MSII24
12C
max
driven
50QD80QD24Gd+T1
92.3%MS
4Gd+ T1
2480QDGd+ T124TEAEsMS
ICP-332
ICP-3322TYK2
T202312ICP-332
TYK-2ADIIICP-3324ADEASI
8078.2%12072.5%
16.7%(p<0.0001)ICP-33280120EASI50EASI 75EASI 90EASI50%75%90%
(IGA)0/1EASI 758012064%/64%EASI 758%(p<0.0001)(TRAEs)
IIIICP-332AD III2024ICP-488
ICP-488TYK2TYK2
JH2IL-23IL12IIFN
ICP-488ICP-488I
(PK)ICP-488136ICP-488
3-12ICP-488<1.5PK4ICP-488
6PASI
13.8%23.7%
6PASI 50 0%42%TEAETRAEICP-488TEAETRAEICP-488
II II2024
ICP-B02 (CM355)
ICP-B02CD20 CD3 TT
BICP-B02SCIVNHLI/II
BB
ICP-B02
ICP-923 ICP-923IL-17AIL-17
IL-17A
IL-17AIL-17AAIL-17AFIL-17R
ICP-723ICP-189ICP-B05ICP-033
ICP-723 (Zurletrectinib)
ICP-723IINTRK
12+80%-90%ORRZurletrectinibTRKTRKi
2≤≤12IND20237CDEPR
20242025NDA
ICP-189 ICP-189SHP2
IaICP-189
120QDDLTAE3160QDICP-189120ICP-189MAPKDUSP6
90%IC
ICP-189201PR14ICP-189ArriVentfurmonertinibEGFR
NSCLCI20243ICP-192 (Gunagratinib) Gunagratinib
FGFRI
ICP-192II
202312023ASCO-GIgunagratinibIIa
/
Tafasitamab/
2024
2024
1.0
2.0
ICP-248ICP-B02TafasitamabICP-490ICP-B05
MMNHLMZL
?B
CLL/SLLMCLMCDDLBCLMCLNHL
BT
B
ITPIIPoCIII
SLEIIaSLE
BTKIIb
NMOSDIICSU
TICP-332ADIIPoCICP-488PoCTSLELNIBD
BICP-332ICP-488ICP-923T
ICP-
ICP-189ICP-B05ICP-033
IND
ICP-B02ICP-B05Tafasitamab
ICP-022/
INDEnabling
PhIIIPHIaPhII*
ExpectedNDAFilingPHIbPhII**
BTK
r/rCLL/SLL20201225r/rMCL20201225r/rMZL202012251L:CLL/SLLMZLconfirmatory1L:MCDDLBCL
CHN,
CHNCHN2024
NDA
ICP-B02CD3xCD20ICP-248
NHLBCL2ICP-490MM/DLBCL/E3???
Tafa+LEN,r/rDLBCLICP-B04/Tafasitamab
CD19
IV&SC
CCR8ICP-B05
HK20241L:MCL
r/rDLBCLIND
ICP-248
NHL
1LCLL/SLL
r/rMCL2024US
INDEnabling
PhIIIPHIaPhII*
Filed
PHIbPhII**
ICP-B05
pan-FGFRICP-192/Gunagratinib
pan-TRKNTRKICP-723/Zurletrectinib
VEGFR,DDR1ICP-033
SHP2ICP-189
CCR8
SLEMS
BTK
ITPNMOSDTYK2–JH1ICP-022/ICP-332
TYK2–JH2ICP-488
+EGFRi
SG
NDA
?
BTK?
BTK2022CLL/SLLMCL2024
MZL2023?
CSCOCLL/SLLMCLBTKDLBCLpCNSL
20231231738.520231231670.72022123118.5%330
DOT2024
TafasitamabICP-248ICP-B02ICP-490ICP-B05
NHLMM
NHLMM(i)(ii)FDAEMACD19TafasitamabDLBCL(iii)
BCL-2CD20xCD3E3CCR8(iv)
1,100CLL/SLLMCL
MZLMZLBTK
MZL
MZLBNHL
8.3%MZL
MZL20234NMPAMZL
MZLBTK2023616ICML
MZLIRC2014ORR
IV75.9%
24.3IRCORR58.9%DoR34.3
PFS12PFS82.8%OS91%TRAE
III(R2)R2MZLASH 2023(Jiadai Xu, Lu-Ya Cheng, Yang Ke, et al. Blood 2023142 (Supplement 1)6146.)MZLMZL103(30%)CR6(60%)PR
90%13.07.824.7PFS6PFS100%OS202356
89.6
3.017.8ORR75% (6/8)1SD1PD
MCL
MCLBB
MCL60
MCL
CR
202352BloodBlood AdvancesMCL
MCL10620236946.98
CTORR83%
35.8%3.8%CRu43.4%
25.79
24.94OS56.21
MCLII20232024FDABTD
MCL
(OLR)MCLII(Huilai Zhang,Liping Su,Lihong Liu, et al. Blood 2023142 (Supplement 1)736.)21(75.0%)616(76.2%)CR5(23.8%)
PR100%2118
MRD18MRDPB-MRDMRDBMMRDDORPFS12DORPFS
90.9%92.3%
1L CLL/SLL
IIICLL/SLL
IRCPFS202353III1L CLL
2024NDA
1L MCL
MCLIII
1L DLBCL-MCDDLBCLNHL100
MCD1L DLBCL
IIIR-CHOPR-CHOPMCDDLBCL
40%DLBCL
R-CHOP+XMCDBNF-KBBTK
TITKCD20NKADCC
R-CHOPMCDDLBCL
20226ASCOR-CHOPMCD DLBCL14MCD DLBCL
1508R-CHOPR-EPOCH6RICER-CHOPR2
CRR75%66.67%
MCDDLBCL
MCDDLBCL
CLL/SLL
IICLL/SLL15080CLL/SLL
202362652.442.5%
ORR93.8%CR30%1.84DOR
PFS5250
CLL/SLLBTKCRAE
pCNSL
EHA2023
pCNSLII
pCNSLND pCNSL
ORRpCNSLpCNSL
2022ND pCNSLCNSLND pCNSLORR88.9%100%CR53.9%61.8%ND pCNSL
PFSmPFS6PFS63.6%100%
60%CNSLORR60%
86.7%mPFS9.83
mPFSBCRMYD88
MOA
BBBBBB15021.6BBB58.6%
pCNSL
ICP-248BCL-2
BTKBCLL/SLLMCLCLL
CLLBTKPFS
BTKOSBTK
uMRD
BCL-2BCL-2B
BCL-2BTKCLL/SLLMCL
CLL/SLL
ICP-248BCL-2CLL/SLLMCLICP-B04 (Tafasitamab)
CSCOTafasitamabASCTDLBCL
Tafasitamab
TafasitamabDLBCLTafasitamab
TafasitamabDLBCLII
2024CDENDA
2025NDAIITafasitamabDLBCL
IRCORRDCRDoRPFSTTPTTROS
Tafasitamab
ASCTDLBCLTafasitamabDLBCLDLBCLCD19
B-NHLB-NHL
TafasitamabBLAASCTDLBCL
TafasitamabDLBCLICP-248ICP-248B2BCL-2BCL2BCL-2
ICP-248ICP-248DDIBLC2
ICP-248BCL-2
ICP-248CLL/SLLNHL
II
ICP-248BCLL/SLLMCLNHLBCL-2ICP-248100QD RP2DCRuMRDORR100%CLL/SLLIND20243CDEICP-24820241FDA
ICP-B02 (CM355)
ICP-B02
BCD20xCD3
TDCCICP-B02IVSCIVSCFLDLBCL13ICP-B02≥6ORR100%SC9
ORR100.0%(9/9)(CRR)77.8%(7/9)2CRDLBCL
ICP-B02NHL
IND20243CDE
0.5/1.5/6
ICP-B02SCIVNHLI/IIB
BICP-B02
ICP-490ICP-490CRBN E3
IMiDTPD
CRL4CRBN E3ICP-490IKZF1IkarosIKZF3Aiolos
ICP-490MMDLBCL
ICP-490CRNB
ICP-490ADCCCD38daratumumab
20234182023AACRICP-490
ICP-490MMNHLDLBCL
IC50ICP-490
ICP-490ICP-490MMDLBCLICP-490ICP-490IL-2BCD38DaratumumabMMNHL
ICP-490BTK
MMIICP-490
MRICP-490PDAiolos (IKZF3)Ikaro (IKZF1)20239INDCDEICP-490dexamethasoneICP-490MM
ICP-B05 (CM369)ICP-B05C-C8CCR8CCR8TMETTreg
ICP-B05CCR8TregsADCCTregsTMEICP-B05
T(Treg)Tregs
TregsICP-B05
IICP-B05NHLICP-B05
150NHLICP-B05DLT3AE (TRAE)PK
TNHLPRICP-B05
BT
BT
AD:
LN:
ITPMSNMOSD
CSU
AD
LNIBDSLE
ICP-332(TYK2i-JH1)ICP-488(TYK2i-JH2)
T
(BTKi)B
| IBD: | ||
ICP-923(IL-17i)
SLE:
ITP:
NMOSD:
CSU:
BITPPoCGCIVIG2023
IIISLEIIa
SLEBTKIIbIINMOSDCSU
HS
T
TYK2ICP-332ICP-488TADSLELNCDUC
BICP-332ICP-488T
B—
BTKTECB
BCRB
BTKBTK
ITP
ITP
ITP
T
ITP100,00023.6100,0009.5
CD20
BTKBITPB
BTKITPITP
2023ITPII
IIITP
III5010
/L27420232633
50QD30QDITP
50QD(GC)(IVIG)36.4%33125040%156
1283.3%1210
14246450x10
/L22GCIVIG5075.0%86
ITPTRAE122023612EHA2023ITPII
ITPPoCIII20231020242025IIITP
BTKITPBTK
SLEBTKBCRBSLE
SLE
2025SLE1.0620202025
0.7%2030SLE1.0920252030
0.5%
SLEIIa
SLE1111125080100IIa
508010012SRI-4
35.7%50.0%61.5%64.3%
GC3C4IIa2022EULAR
5080100
SRI-4 12
N=55IIaIIb40
IIbSLESLESLE
507548SRI-4
C3C4dsNDA4850% CDE
IIaSLEBTK
SLEMSIIRRMS
MSII2412
Cmax driven4T1241250QD80QDGd+T12492.3%MS
50QD24Gd+T1 (PHS , N=115)
QD=BID=CI=Gd+ =
50QD50QD50BID80QD
6.45 (3.62, 11.52)2.10 (0.62, 7.11)1.08 (0.30, 3.81)0.50 (0.09, 2.74)
67.4 (-22.0, 91.3)83.3 (33.2, 95.8)92.3 (56.5, 98.6)
0.09580.01140.0037
80QDGd+T124
TEAEMSALT/AST>8xULN50BID50QD80QDFDA
2023215
2023215
BMSSPMSPPMSIIMSOLE
MSBTKNMOSDNMOSD
45-650.445/100,000
4.711
BTKBB
BTKBTKBTKNMOSD
IITII
T— TYK2ICP-332ICP-332TYK2TYK2JAKIL-12/IL-23IFN
T17TH17TH1B
ADICP-332TYK2400JAK2JAK
TYK2ICP-332
IBD
PharmaIntelligence12
0.96-22.6%1.2-17.1%2030100Frost & SullivanAD201965.7
203081.71.7%JAllergy Clin Immunol Pract. 2021 Apr9(4)1488—1500AD33%90%
AD
ICP-332
202312IIPOCII
ICP-332
75AD80mg QD120mg QD 25
ICP-3324ADICP-33280120EASI 50EASI 75EASI 90EASI≥50%75%90%IGA0/1
*p<0.0001
-16.7%
-80%-70%-60%-50%-40%-30%-20%-10%0%
-78.2%*
-72.5%*
p<0.0001
20%
8%0%10%20%30%40%50%60%70%80%
EASI50EASI75
72%*
64%*64%*90%88%*
*p<0.0001
4EASI 50EASI 75(FAS)4 — (FAS)
ICP-33280QD
ICP-332120QD
ICP-332 80ICP-332 120(EASI)(+/- SE)(%)
ICP-332 80ICP-332 120
(DLQI)
p<0.01
(N=25)
ICP-33280(N=25)
ICP-332120(N=25)D8/W1-3.3(-4.8,-1.9)-6.5(-8.0,-5.1)-6.8(-8.4,-5.3)
ppp
0.00270.0018
D15/W2-2.2(-4.2,-0.2)-8.7(-10.7,-6.7)-7.9(-9.9,-5.9)
<0.00010.0002
D29/W4-1.2(-3.3,0.9)-10.8(-12.8,-8.8)-8.9(-11.0,-6.8)
<0.0001<0.0001
ICP-332 80ICP-332 120
80120EASI
78.2%72.5%16.7%(p<0.0001)80120EASI 7564%64%8%p<0.000180EASI 7556%EASI 9040%IGA0/132%NRS≥4
56%p<0.01
(NRS) (p<0.01)80120ICP-3322
p<0.01ICP-332AD
(TRAE)
II2024AADICP-332 IIADADICP-332AD III
AD III2024ICP-488ICP-488TYK2JH2JH2TYK2
JH2TYK2ICP-488
TYK2TYK2 JH2IL-23IL-12IIFNICP-488
SLELNIBDICP-488ICP-332TYK2
T23(IL-23)T17(Th17)
2022
1.252%3%
ICP-488IIICP-488
136312
ICP-488PKSADPK
?SADPK?7.2-11.2
MADPK
0122436486072
-1
(+SD)(ng/mL)
1(N=6)3(N=6)6(N=6)12(N=6)24(N=7)36(N=6)
?6QDCavIC50TYK2
0122436486072
-1
(+SD)(ng/mL)
3QD(N=6)6QD(N=6)12QD (N=6)
ICP-488ISADICP-488IMAD
ICP-488136ICP-4883-12ICP-488<1.5
PK
1Histologic,molecularandclinicalimprovementinmoderate-to-severepsoriasis:ResultsfromaPhase1btrialofthenovelallostericTYK2inhibitorNDI-0348582Nimbus2022-05-19SDINDI-034858PhaseIbResultsPoster.pdf
0%10%20%30%40%
N=7
ICP-488 6QDN=12
14%
38%
0%10%20%30%40%50%
ICP-4886QD(5/12)
42%
40%
TAK-27930QD(2/5)
4ICP-4886
PASI(13.8%)23.7%6PASI 50
(0%)42%TEAETRAEICP-488ICP-488PKIIICP-488II2024
ICP-723
ICP-189NSCLCICP-B05ICP-033
ICP-723 (Zurletrectinib)
ICP-723TRK
TRKTRKNTRKTRKTRKICP-723TRKA/B/CTRKAG595RG667CICP-723TRK
TRKTRKATRKBTRKC
NTRK1NTRK2NTRK3TRK
NTRKNTRKNTRK
NTRK1218ICP-723CDE20237212IND
ICP-723NTRK12II20242025NDA80%-90%ZurletrectinibTRK
TRKi2≤≤12IND20237CDEPR
ICP-189ICP-189SHP2ICP-189
SHP2RAS-MAPK
PD-1SHP2
ICP-189ICP-189EGFR
KRASMEKPD-1ICP-189
PDICP-189p-ERKDUSP6 mRNA
IaICP-189120QDDLT3AE (TRAE)160QDICP-189PK120ICP-189MAPKDUSP6IC90ICP-18920
1PR142024Ia
ICP-189 IbEGFR
PD-12023714ArriVent BiopharmaArriVent
SHP2ICP-189ArriVentfurmonertinibEGFRNSCLC
ICP-189furmonertinibEGFR
ICP-189EGFRiIb20243ICP-189
2023ICP-189INDFDAICP-192 (Gunagratinib)Gunagratinib
FGFRFGFR
7.1%
GunagratinibFGFR
FGFRgunagratinibFGFR
20231GunagratinibCCAIIaICP-19218CCA17
5.57ORR52.9%17
9DCR94.1%1716mPFS6.93
95% CI5.42— TRAE
FGFRgunagratinibCCAFGR2
(52.9%)2023IIICP-033ICP-0331DDR1
VEGFRICP-033
ICP-033/
ICP-033I
PROTACXDC
50,000
GMP
NMPABTK
2022
2023
202530,000
CMC
70,381
8.05(3)
18A.0918A.112023512B
202359
20231231202411220242232,198,000
6.004.54
11.3
20241548,000202427202421,650,000
123120232022
%%
671,58290.9566,75590.666,9559.158,6499.4
738,537100.0625,404100.0
20221231625.418.1%20231231738.520221231
566.818.5%20231231
671.6
123120232022
%%581,11495.2471,17097.8
28,9884.810,8372.2
610,102100.0482,007100.0
20221231482.026.6%20231231610.120231231
82.6%2022123177.1%5.5%
20221231198.220231231244.220221231136.955.420231231192.3
20221231639.117.5%20231231751.2
123120232022
%%
291,71238.8196,82630.8255,43634.0223,09534.9
29,0453.958,1649.159,9978.043,0836.7114,98615.3117,97118.5
751,176100.0639,139100.0
(i) 196.894.9
291.7
(ii) 223.132.3255.4
(iii) 58.229.229.0
(iv) 43.116.960.0
(v) 118.0
3.0115.0
20221231181.611.920231231193.5
10.8
123120232022
%%79,90441.378,00843.027,83614.434,35718.931,55316.335,15919.416,7378.611,2976.29,7045.06,8953.8BTK10,7665.6——17,0208.815,8408.7
193,520100.0181,556100.0
20221231438.620231231366.9
123120232022
%%
171,82946.8234,34553.4155,11542.3143,10532.68,2232.236,9568.431,7248.724,2055.6
366,891100.0438,611100.0
20221231291.22023123192.7
2023
20221231
3.42023123154.0
202312314.9202212319.7
2022123117.02023123135.1
2023
123120232022
307,638127,825113,99495,344119,09565,322
—313,2908,224,5968,697,927
8,765,3239,299,708
5,000—134,905118,597
—4,242667,717727,55212,0087,75723,23320,1121,251,1311,197,168
2,093,9942,075,428
6,671,3297,224,280
202312316,671.3
8,224.6307.6
114.0
119.1667.7
134.91,251.1
123120232022248,942127,822
58,6963
307,638127,825
2021
2022123195.320231231114.0(i)2022123133.65.42023123139.0(ii)2022123145.0
17.52023123162.5
12312023202239,04433,55762,54044,98710,39012,1472,0204,653
113,99495,344
2022123165.320231231
119.1
2023123120221231313.3
123120232022124,207111,18610,4327,33519966
6710
134,905118,597
20221231727.620231231667.7(i)
20221231104.120231231
58.2(ii)20221231
32.62023123115.3(iii)2022123151.42023123138.3
(iv)20221231459.520231231476.3
123120232022
58,190104,05052,99957,01415,25332,58011,8537,62838,33651,391476,336459,51714,75015,372
667,717727,552
123120232022
5,000—23,23320,112476,336459,5171,251,1311,197,168
26,300—43,64735,439305,577287,761
2,131,2241,999,997
202212312,000.0202312312,131.2
20221231
286.020231231280.9
20221231653.220231231759.8
20221231284.120231231
293.8
2022123141.32023123139.0
2022123111.7202312315.7
20221231
28.02023123152.4
123120232022
4.24.5
8,697.98,224.6313.3
1,197.21,251.1
127.8307.6
65.3119.1
727.6667.7
20203238.95250,324,0000.0000023,883
2,240.4
2020323H.10
2020415
37,548,00015%
322.59
2021210210,508,00014.45
2021232021210
2022921264,648,2170.000002
11.03
2,778.82
202312318,224.6202212319,011.2
202110820211229
20231231
10.5
2023123120231231
20231231
100%20.8%20221231
18.8%
202312311,251.1
305.6
31.3
476.3
156.820235
400.02023123133.8
366.2
20231231
20231231
20231231202312312022
2024627
20246242024627
2024
183171712-1716
201511320203232022921
202362
20236220235
— 2023327
2023327—
2023714— 20231011
13.51(2)
20231011— 20231218
20231217
(i)(ii)
(iii)
20231213
13.51B(1)
C1
C.2.1
(i)(ii)
(iii)
C3
202398200
1,191,0006,876,550202312311,011,000180,000202311820231228
202320239451,00065.722,627,610202310560,0005.585.343,057,470202311180,0006.666.461,191,470
1,191,0006,876,550
(1)
(2)(3)
20231231
20231231
3.10(2)3.21
20231231
2,415.67202312311,499.6
62.1%
2023
20231231
50%1,207,835411,998150,448261,5502026
40%*966,268696,20163,004633,1972026
10%241,56747,31626,01621,3002024
2,415,6701,155,515239,468916,047
* 2023
20212202122
Gaoling Fund L.P.YHG Investment L.P.Vivo Opportunity Fund, L.P.210,508,000
16.33%14.04%
14.45421.023,041.44210,508,000
14.45202122
15.723,041.843,041.442021210
2023123120221231
2023
20231231
(i)
IND
231,104
(1)
10,871
2027
(ii) 522,373116,076
(iii) 272,889304(iv) 678,13244,149
3,041,4401,704,4981,336,942171,4001,165,542
1. 202122
20229212,919.07
140.25
2,778.82
20229162022916
20231231
2023
20231231
1,494,220.61,494,220.6251,353.31,242,867.32027116,146.6116,146.690,268.525,878.12027273,851.4273,851.4114,706.7159,144.72027
60,952.360,952.328,656.232,296.12027833,644.7833,644.7468,728.4364,916.32027
2,778,815.62,778,815.6953,713.11,825,102.5
2023123120231231
20232022
738,537625,404(128,435)(143,397)
610,102482,007
244,153198,199(366,891)(438,611)(751,176)(639,139)(193,520)(181,556)
(92,674)(291,167)
(53,963)3,396
(268)(100)
(4,900)(9,711)
(35,069)(17,045)
(644,206)(893,727)
(1,426)—
(645,632)(893,727)
(631,263)(886,593)
(14,369)(7,134)
(645,632)(893,727)
0.370.60
20231231
20232022
(645,632)(893,727)
113,544429,445
113,544429,445
(532,088)(464,282)
(517,719)(457,148)
(14,369)(7,134)
(532,088)(464,282)
20231231
20232022
759,764653,163293,837284,103
3,1253,12539,00741,305
5,66011,71252,41328,042
1,153,8061,021,450
119,09565,322
307,638127,825113,99495,344
—313,2908,224,5968,697,927
8,765,3239,299,708
134,905118,597
—4,242667,717727,552
12,0087,757
5,000—23,23320,1121,251,1311,197,168
2,093,9942,075,428
6,671,3297,224,280
7,825,1358,245,730
20232022
26,300—43,64735,439305,577287,761268,906278,203
644,430601,403
7,180,7057,644,327
23237,147,8257,597,078
7,147,8487,597,101
32,85747,226
7,180,7057,644,327
1.
2015113Ogier Global (Cayman)Limited, 89 Nexus Way, Camana Bay, Grand Cayman KY1- 9009 CaymanIslands
20203232022921
1100%—
—100%InnoCare Pharma Inc. 3—100%InnoCare Pharma Australia Pty Ltd.10—100%
(a)
80,000,000—100% 10,000,000—100%
(d)
66,474,400—
93.39%
4,000,000—100% 1,000,000,000—93%
(b)
2,000,000—100%
(a) (c)
30,000,000—100%(a)
(b) 202310261,152,000.00
50%100%
(c) 202395(d) 202322349,225,10066,474,400
91.08%93.39%
2.1
20231231
(a)(b)(c)
2.2
(a) 1
(b) 8
(c) 12
(d) 12
—
2.3
2020
1,4
12022
202411
202511
202020225
—
102810
1028
—
—
202411162019112020
2022
20202022
3.
(a)
20232022673,134568,03565,40357,369
738,537625,404
(b)
202320221,153,3921,020,695
414755
1,153,8061,021,450
10%
20232022A249,438224,090B111,890101,386C93,42181,916
454,749407,392
4.
20232022
738,537625,404
(a)
20232022
671,582566,755
59,75857,369
5,645—1,5521,280
738,537625,404
673,134568,035
65,40357,369
738,537625,404
678,779568,035
59,75857,369
738,537625,404
20232MS
BTK
20232022
17,7837,797
(b)
3090
1231
20232022
—17,783
20232022
41,00646,159192,333136,914
10,4728,48634283
244,153191,642
—6,557
244,153198,199
5.
16.5%2022
16.5%
2,000,00020222,000,0008.25%20228.25%
16.5%202216. 5%
25%15%202315%202215%15%
15%2022[2022]1320221120241231
1,000,0003,000,00025%20%
202320%202220%20%
50,000,00025%202225%
21%202221%
202320221,426—
20232022(644,206)(893,727)
25%(161,052)(223,432)
16,74797,15234,60065,183
—(111,915)(62,491)
204,349103,983
16,53618,1487351,4571,364—
1,426—
2,693,952,000
6.
202312312022
7.
123120232022
(631,263)(886,593)
20232022
1,687,4701,479,565
202320221231
202320221231202320221231
8.
20232022276,778127,957
31,261—
(401)(132)
307,638127,825
20232022248,942127,82258,6963
307,638127,825
20232022
13231268100
401132
20231231
276,7780.14%401
20221231
127,9570.10%132
9.
20232022124,207111,186
10,4327,335
19966
6710
134,905118,597
10.
20231231202411220242232,198,000
6.004.5411.3020241548,000202427202421,650,000
AD
ALLAML
ASH
BBBT
BBioDuro Inc.
BiogenBiogen Inc.BIIB
BTDBTKBTK
CD20BCD20MS4A1
BCDENMPA
C1
CLLCNSL
99692015113
2020323
DLBCLB
DLT
EULARFGFR
FL
GMP
20199
IBDICP-192
IL-2-2IL-12-12IL-23-23IND
IRCITKTITP
JAK
2020323
MCDB(DLBCL)
MYD88L265PCD79BMCD
MCLB
C3
MSMZL
NDANMOSD
NMPA
NRDLNTRK
FGFR(FGFR)TRK
PD
PK
2020311
R/Rr/rR-CHOP
RICE
264,648,2172022921
SC
0.000002
SHP2RAS
SLESLLSRISLE
T
TTBNK
TDCCTTRK
TYK22
U.S.
FDAFDA
VivoVivo Opportunity Fund, L.PVivo Capital VIII, LLC
WM
2024328